Oliver M. Bernhardt

Oliver M. Bernhardt

Auto-generated profile, based on publicly available information

Oliver M. Bernhardt

Biognosys AG, Schlieren, Switzerland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2019 in Molecular Omics
Verified
Journal Article
Open access
PDF file
JMJan Muntel
Jan Muntel
TGTejas Gandhi
Tejas Gandhi
LVLynn Verbeke
Lynn Verbeke
OBOliver M. Bernhardt
Oliver M. Bernhardt
TTTobias Treiber
Tobias Treiber
LRLukas Reiter
Lukas Reiter
Comprehensive proteome quantification is crucial for a better understanding of underlying mechanisms of diseases. Liquid chromatography mass spectrometry (LC-MS) has become the method of choice for comprehensive proteome quantification due to its power and versatility. Even though great advances have been made in recent years, full proteome coverage for complex samples remains challenging due to the high dynamic range of protein expression. Additionally, when studying disease regulatory proteins, biomarkers or potential drug targets are often low abundant, such as for instance kinases and transcription factors. Here, we show that with improvements in chromatography and data analysis the single shot proteome coverage can go beyond 10 000 proteins in human tissue. In a testis cancer study, we quantified 11 200 proteins using data independent acquisition (DIA). This depth was achieved with a false discovery rate of 1% which was experimentally validated using a two species test. We introduce the concept of hybrid libraries which combines the strength of direct searching of DIA data as well as the use of large project-specific or published DDA data sets. Remarkably deep proteome coverage is possible using hybrid libraries without the additional burden of creating a project-specific library. Within the testis cancer set, we found a large proportion of proteins in an altered expression (in total: 3351; 1453 increased in cancer). Many of these proteins could be linked to the hallmarks of cancer. For example, the complement system was downregulated which helps to evade the immune response and chromosomal replication was upregulated indicating a dysregulated cell cycle.

1 April 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
FMFränze Müller
Fränze Müller
LKLars Kolbowski
Lars Kolbowski
OBOliver M. Bernhardt
Oliver M. Bernhardt
LRLukas Reiter
Lukas Reiter
JRJuri Rappsilber
Juri Rappsilber
Quantitative cross-linking mass spectrometry (QCLMS) reveals structural detail on altered protein states in solution. On its way to becoming a routine technology, QCLMS could benefit from data-independent acquisition (DIA), which generally enables greater reproducibility than data-dependent acquisition (DDA) and increased throughput over targeted methods. Therefore, here we introduce DIA to QCLMS by extending a widely used DIA software, Spectronaut, to also accommodate cross-link data. A mixture of seven proteins cross-linked with bis[sulfosuccinimidyl] suberate (BS3) was used to evaluate this workflow. Out of the 414 identified unique residue pairs, 292 (70%) were quantifiable across triplicates with a coefficient of variation (CV) of 10%, with manual correction of peak selection and boundaries for PSMs in the lower quartile of individual CV values. This compares favorably to DDA where we quantified cross-links across triplicates with a CV of 66%, for a single protein. We found DIA-QCLMS to be capable of detecting changing abundances of cross-linked peptides in complex mixtures, despite the ratio compression encountered when increasing sample complexity through the addition of E. coli cell lysate as matrix. In conclusion, the DIA software Spectronaut can now be used in cross-linking and DIA is indeed able to improve QCLMS. Graphical Abstract Highlights Quantitative cross-linking mass spectrometry (QCLMS) was automated by Spectronaut. Data-independent acquisition (DIA) was adapted to QCLMS. Accuracy and precision of quantitation improves with DIA over DDA. QCLMS is now ready for use in complex samples.

26 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CBChristopher R. Below
Christopher R. Below
OBOliver M. Bernhardt
Oliver M. Bernhardt
SKStephanie Kaspar-Schoenefeld
Stephanie Kaspar-Schoenefeld
SWSander Willems
Sander Willems
ECEdoardo Coronado
Edoardo Coronado
LRLukas Reiter
Lukas Reiter
Data-independent acquisition mass spectrometry is essential for comprehensive quantification of proteomes, enabling deeper insights into cellular processes and disease mechanisms. On the timsTOF platform, diagonal-PASEF acquisition methods have recently been introduced to directly and continuously cover the observed diagonal shape of the peptide precursor ion distributions. Although diagonal-PASEF has shown great promise, its broad adoption as a routine workflow has been hampered by a lack of available algorithmic solutions and a paucity of demonstrated real-world applications. Here, we conducted a systematic and comprehensive optimization of diagonal-PASEF for 17-minute gradients on the timsTOF HT in conjunction to Spectronaut 19. We demonstrate that Spectronaut 19 fully supports all tested diagonal-PASEF methods independent of the number of slices or overlaps and with minimal user intervention required. Using our optimized analysis strategy we coupled diagonal-PASEF acquisitions to retention time down-sampling by summation (RTsum), thereby providing a novel mode of analysis of this data that exploits the fast-cycling nature of diagonal-PASEF methods. Through the combination of RTsum with diagonal-PASEF, we demonstrate that this strategy yields higher signal-to-noise ratios while retaining the peak shape for analytes of interest. Importantly, combining RTsum with diagonal-PASEF improved overall identifications and quantitative precision when compared to dia-PASEF with static or variable quadrupole isolation widths and across different input amounts for cell line injections. We also tested the performance of diagonal-PASEF in controlled quantitative experiments where diagonal-PASEF outperformed dia-PASEF in the overall number of retained candidates, quantitative precision and identifications on peptide level. These data indicate that RTsum demonstrates a positive use case of the high sampling rate of diagonal-PASEF. Collectively, our findings imply that diagonal-PASEF methods are superior for peptide and protein level analyses especially at lower input amounts.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
ISIlja E. Shapiro
Ilja E. Shapiro
LRLuca Räss
Luca Räss
CBChristopher R. Below
Christopher R. Below
MTMarco Tognetti
Marco Tognetti
TTTikira Temu
Tikira Temu
LRLukas Reiter
Lukas Reiter
Colorectal cancer (CRC) is currently the second most common cause of cancer related mortality in the world. One of the hallmarks of CRC is its complex mutational landscape that contributes to the derivation of neoantigens which aid the immunosurveillance of the cancer. Immunopeptides play an essential role in adaptive immunity by activating and ensuring T-cell specificity. Mass spectrometry (MS) is currently the only technology that can measure and identify the immunopeptide profiles of biological samples at a large scale, however, MS-based studies are frequently limited by sample input and poor scalability. Here, we introduce a semi-automated workflow requiring low sample input to robustly identify immunopeptides and apply it to a cohort of fresh frozen, high quality CRC samples (Indivumed) for immunopeptide profiling and neoantigen identification. We initially optimized a workflow that allowed the native lysis and sequential immunoprecipitation of class-I and class-II immunopeptides while ensuring scalability and reproducibility. The immunopeptides were thereafter subjected to our True Discovery FAIMS-DIA LC-MS/MS platform which we supported through a specific DDA library and searched the resulting data with Spectronaut (Biognosys) by applying a 1% FDR threshold. We utilized data from WGS on both tumor and adjacent normal tissue for the calling of high-confidence somatic variations (Indivumed) and the definition of the resulting neoantigens. We characterized 131,578 unique immunopeptides from 15 mg of fresh-frozen tumor tissue across 20 patients with CRC lesions that mapped to 12,488 genes. On average we identified 9,767 class-I and 16,445 class-II immunopeptides from all patients indicating significant inter-patient heterogeneity. Overall, we found the identification numbers of class-II immunopeptides to be more variable than that of class-I which might be linked to immune infiltration levels. From our pool of identified immunopeptides, we were able to detect 16 class-I and 29 class-II neoantigens, covering 87% of the microsatellite instability-high (MSI-H) samples in the cohort. Coverage of both classes was essential to increase neoantigen discovery as 53% MSI-H samples had neoantigens mapping to a single class. Interestingly we also detected a significant correlation between the mutational burden and the number of detected neoantigens in our patient cohort suggesting that the genetic set up of the cancer might influence the repertoire of presented neoantigens thereby controlling immunosurveillance. In summary, we have established a scalable and efficient pipeline for cell line and tissue immunopeptidomics for both class-I and II immunopeptides. Our pipeline generates high-quality identifications and can be deployed to help shed light on immunopeptidomics heterogeneity through large-scale profiling of patients as exemplified in the case of MSI-H CRC. Citation Format: Ilja E. Shapiro, Luca Räss, Christopher R. Below, Marco Tognetti, Tikira Temu, Oliver M. Bernhardt, Roland Bruderer, Jonathan Woodsmith, Lukas Reiter. Complementarity of class I and II neoantigen mapping in MSI-high colorectal cancer in needle biopsy size tissue samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2991.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
ISIlja E. Shapiro
Ilja E. Shapiro
LRLuca Raess
Luca Raess
MTMarco Tognetti
Marco Tognetti
TTTikira Temu
Tikira Temu
OBOliver M. Bernhardt
Oliver M. Bernhardt
LRLukas Reiter
Lukas Reiter
Human leukocyte antigen-associated peptides, known as immunopeptides, play an essential role in adaptive immunity by activating and ensuring the specificity of T-cells. The identification and quantification of the immunopeptidome bear the potential to enable personalized treatments, especially in cancers, vaccines, infectious, and autoimmune diseases. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. However, the usually high sample input amount and poor scalability are limiting. Here, we introduce a semi-automated workflow to robustly identify immunopeptides from low amounts of cultured cells and tissue samples by systematically optimizing each step of the sample preparation and acquisition. We optimized the native lysis and immunoprecipitation workflow while ensuring scalability and reproducibility. Leveraging the magnetic properties of the beads, 1,000 samples can be processed within a week by a single operator. The established sample preparation offers high reproducibility and identifications of good quality. For class-I immunopeptides, >60% of the peptides identified are 9-mers, >80% predicted strong binders, and the expected amino acids are enriched at the anchor positions. For class-II, >50% of the peptides identified are 14-to-16-mers, and >50% are predicted strong binders. Furthermore, the pipeline is highly sensitive as we could still identify over 2,800 class-I immunopeptides when processing as little as 2.5 mg fresh frozen tissue and >9,000 class-I and >12,000 class-II immunopeptides when preparing 10 million JY cells. Overall, the pipeline is scalable, highly reproducible, and results in high-quality identifications while supporting very limited sample input. Finally, we measured a cohort of 12 cancerous and matched healthy lung tissues from as little as 15 mg tissue, whereby we could identify >11,000 class-I immunopeptides and >9,000 class-II on average. For class-I, matched samples clustered together, while >3,000 immunopeptides were upregulated in the cancer tissues, with a significant enrichment for proteins related to lung cancer. Overall, we established a scalable, efficient pipeline for cell line and tissues immunopeptidomics for class-I and II that generates high-quality identifications and that only requires small amounts of input material and is ready to shed light into immunopeptidomics heterogeneity through large-scale profiling of patients. Citation Format: Ilja E. Shapiro, Luca Raess, Marco Tognetti, Tikira Temu, Oliver M. Bernhardt, Yuehan Feng, Roland Bruderer, Lukas Reiter. Discovery of MHC class I and class II neoantigens in lung cancer in needle biopsy tissue samples using an optimized high-throughput workflow [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1374.